Vigilant Capital Management’s Sempra SRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-56
Closed -$4K 501
2022
Q4
$4K Hold
56
﹤0.01% 465
2022
Q3
$4K Sell
56
-200
-78% -$16.2K ﹤0.01% 532
2022
Q2
$19K Buy
256
+192
+300% +$15.4K ﹤0.01% 372
2022
Q1
$5K Hold
64
﹤0.01% 530
2021
Q4
$4K Sell
64
-52
-45% -$3.29K ﹤0.01% 601
2021
Q3
$7K Buy
+116
New +$7.66K ﹤0.01% 590
2020
Q2
Sell
-398
Closed -$22K 351
2020
Q1
$22K Hold
398
﹤0.01% 252
2019
Q4
$30K Hold
398
﹤0.01% 360
2019
Q3
$29K Hold
398
﹤0.01% 295
2019
Q2
$27K Hold
398
﹤0.01% 301
2019
Q1
$25K Hold
398
﹤0.01% 310
2018
Q4
$22K Hold
398
﹤0.01% 318
2018
Q3
$23K Hold
398
﹤0.01% 349
2018
Q2
$23K Sell
398
-182
-31% -$9.95K ﹤0.01% 340
2018
Q1
$32K Buy
580
+182
+46% +$9.82K ﹤0.01% 273
2017
Q4
$21K Hold
398
﹤0.01% 298
2017
Q3
$23K Hold
398
﹤0.01% 236
2017
Q2
$22K Hold
398
﹤0.01% 212
2017
Q1
$22K Hold
398
﹤0.01% 216
2016
Q4
$20K Hold
398
﹤0.01% 220
2016
Q3
$21K Hold
398
﹤0.01% 226
2016
Q2
$23K Hold
398
﹤0.01% 214
2016
Q1
$21K Hold
398
﹤0.01% 199
2015
Q4
$19K Buy
+398
New +$19.7K ﹤0.01% 218

Other funds holding SRE

Vigilant Capital Management's SRE Position: Q1 2023 in Review

Vigilant Capital Management sold out of Sempra (SRE) in Q1 2023, closing a stake of 56 shares — an estimated $4K sold.

Vigilant Capital Management first reported a position in SRE in Q4 2015 and held it in 24 quarters. The position peaked at $32K in Q1 2018. 981 funds tracked by Wall St. Rank hold SRE as of Q1 2023.

  • Vigilant Capital Management reported no remaining Sempra position as of Q1 2023 after selling out during the quarter.
  • Vigilant Capital Management sold 56 Sempra shares in Q1 2023, an estimated $4K.
  • Vigilant Capital Management first reported a position in Sempra in Q4 2015 and held it in 24 quarters.
  • Vigilant Capital Management's Sempra position peaked at $32K in Q1 2018.
  • 981 funds tracked by Wall St. Rank held Sempra as of Q1 2023.

Based on Vigilant Capital Management's 13F filing for Q1 2023, filed 1 May 2023.